Novartis’ $2B cancer drug spurs ‘groundbreaking’ PhIII data for prostate cancer
Continuing a streak of upbeat announcements on its radioligand portfolio, Novartis says that their Phase III study of 177Lu-PSMA-617 hit both co-primary endpoints on overall survival and radiographic progression-free survival for prostate cancer patients — setting up a likely approval some analysts believe would be worth more than a billion dollars a year in peak sales.
Investigators tried the treatment on progressive PSMA-positive metastatic castration-resistant prostate cancer patients, comparing it against standard of care. We don’t have the exact data, but Novartis typically holds back specific results for the cancer conferences.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.